Early graft failure (EGF) is a dreaded complication after heart transplantation (HT). Despite several improvements, no effective therapy has been developed and the prognosis is poor. We evaluated the risk factors and clinical impact of EGF. In a consecutive series of 317 HTs performed at a single institution between January 1999 and December 2008, variables associated significantly with EGF were sought in bivariate and multivariable discriminant analyses. The deriving propensity score was used to stratify the study sample in to three groups (low, intermediate and high risk for EGF). Comparisons were performed between the higher-risk group and the remaining population in terms of preoperative features and outcomes. EGF occurred in 10.1% of the overall population (2.9, 3.8 and 23.6%, respectively, in the three groups). Overall, EGF-related mortality was 56.3% (100, 75 and 48%, respectively, in the three groups). Determinants of EGF in the highest-risk group were: redo procedure, valvular cardiomyopathy, status one at transplant, recipient male sex, donor-recipient (D/R) weight mismatch, high inotropic donor support, ischaemic time and first day troponin I release. In conclusion, several donor and recipient features predicted EGF. Since such characteristics are not readily modifiable but synergistically determine the occurrence of EGF, optimization of D/R matching is crucial to prevent it.
INTRODUCTION
Early graft failure (EGF) is one of the most dreadful complications following heart transplantation (HT). Little progress has been made in the prevention of this rare but dangerous condition, indeed, despite the expanded criteria for suitability of potential donors and the increasing complexity of recipient features, techniques of heart protection, algorithms for donor-recipient (D/R) matching along with treatment strategies for EGF have not consistently evolved [1] [2] [3] . As a consequence, this event is still the prime cause of 30-day mortality after HT [4] . Larger studies on risk factors interaction [5] have shown the synergistic effect of donor and recipient risk factors. The purpose of this study was to identify, in a single-centre experience, the risk factors associated with EGF and their interaction and describe the course, treatment and prognosis of EGF.
MATERIALS AND METHODS

Study population and data
Between January 2000 and December 2008, 317 patients underwent HT. Study protocol was approved by the local Ethical Committee which waived the need for consent. Preoperative recipient data, donor-related variables, data about the D/R matching, the procedures, treatments and all clinical perioperative and postoperative outcome data were prospectively entered in a dedicated database.
Surgical methods and graft protection
Donor and recipients were matched for AB0 blood type compatibility and body size. Whenever possible undersized donors (the D/R weight ratio <0.8) were not used in recipients affected by secondary pulmonary hypertension in whom oversizing (the D/R weight ratio >1) was attempted.
Prospective human leukocyte antigen (HLA) matching was not used with the exception of recipients with a high level of panel reactive anti-HLA antibodies who underwent prospective cross-match following the indications of the Department of Transplant Immunology. A coronary angiogram was obtained when indicated by guidelines and logistically feasible; in the other cases, visual evaluation and manual palpation of epicardial coronary arteries prior to harvesting the graft were employed.
High donor inotropic support (dobutamine or dopamine ≥10 µg/kg/min and/or norepinefrine) did not prevent graft harvesting unless the massive dosage (>20 µg/kg/min) was associated with left ventricular ejection fraction <45% in optimal loading conditions. Donor heart procurement was performed using the standard techniques, and the grafts were protected with the infusion of 2 l of cold (4-8°C) Celsior solution in the aortic root and topical cold saline slush. All recipients underwent the standard orthotopic HT using the biatrial technique described by Lower and Shumway. Long ischaemic time was defined as graft ischaemia >180 min, since it had proved an independent risk factor for graft dysfunction in our previous analyses.
Cardiopulmonary bypass weaning and perioperative care
In the early postoperative phase, the transplanted heart allograft was reperfused and circulation supported in a way that maintained haemodynamic stability. Inotropic and vasodilator support were tailored under continuous right heart haemodynamic monitoring. As to pulmonary hypertension treatment, until 2005 prostaglandin-E2 (PGE2) was always used while weaning the patient off cardiopulmonary bypass but, since May 2005, 5-40 ppm inhaled nitric oxide (NO) was used in high-risk patients as starting therapy in a protocol involving the use of oral sildenafil whenever extubation was feasible [6] or in patients with overt right ventricular failure (RVF). Principles of postoperative care have been fully elucidated elsewhere [7, 8] . Briefly, the standard immunosuppressive drug regimen was based on induction therapy with polyclonal antibodies (ATG Fresenius, thymoglobuline). ATG Fresenius was preferentially employed in weaker patients and/or complicated postoperative courses in an attempt to reduce the risk of over-immunosuppression. Calcineurin inhibitors and stertoids were introduced after the recovery of renal function. Antiproliferative agents are added only after extubation and achievement of stable clinical conditions.
Event definition
EGF was defined as a mono-or biventricular low output syndrome with a cardiac index <2 l/min/m 2 , higher filling pressures (right atrial pressure or pulmonary capillary pressure >20 mmHg) in the first 24 h with the need of high inotropic support (dobutamine dose >10 γ/kg/min and/or isoprenaline >0.05 γ/kg/min or need for adrenaline or levosimendan), systemic (nitroprusside, nitroglycerin) and/or pulmonary vasodilators (PGE2, NO and sildenafil), intra-aortic balloon pump (IABP), prolonged intubation with high inhaled oxygen concentrations [9] . Patients experiencing low CO syndrome for technical reasons (two cases of pulmonary artery stenosis and one case of narrow left atrial cuff ) were excluded from the analysis. Acute kidney injury was defined according to the RIFLE criteria as reported elsewhere [8] .
Baseline data of the population Table 1 shows the preoperative characteristics of the 317 recipients, characteristics of the 317 donors utilized and data regarding the procedures and D/R matching.
Statistical analysis
Variables related to preoperative recipient, donor, matching and procedure characteristics were compared (using the χ 2 statistic for categorical variables and the Student's t-test or Wilcoxon signed-rank sum test for continuous variables) between patients developing EGF and the others and then included in a single-step multivariable discriminant analysis in order to create a propensity score for the likelihood to develop EGF. The C-statistic for the propensity model was >0.80. Then, the patient population was divided into three groups corresponding to tertiles of propensity scores. The first two groups (low and intermediate risk) were pooled and the high-risk group was compared with the other patients by bivariate analysis in terms of both preoperative features and outcomes. Data are expressed as the mean ± SD for continuous variables and as percentages for categorical variables. Odds ratio values for outcomes were reported with 95% CI. All statistical analyses were performed with SPSS 17.0 (SPSS Inc, Chicago, IL).
RESULTS
Events
Thirty-two patients (10.1%) experienced low CO syndrome for EGF; 10 cases (3.1%) consisting of an RVF and the other 22 (6.9%) of biventricular failure (BEGF). EGF was the direct or indirect cause of death in 52.9% cases (18 patients; overall deaths were 34, 10.7%). Only one patient (21-years old) was re-transplanted after <24 h of ECMO and died of EGF. The relative mortality of the EGF was 56.5%; 59% for BEGF and 50% for RVF. The incidence of counterpulsation was 25% (27% in BEGF and 20% in RVF). Levosimendan was used in one case (10%) of RVF and three cases (13.3%) of BEGF. Three of the eight (37.5%) patients treated with IABP died (50% with RVF and 33% with BEGF) and similarly two of the four patients (50%) treated with levosimendan (100% in RVF, 33% in BEGF). The incidence of multiple organ failure (MOF) was, respectively, 50% in RVF and 31% in BEGF.
Univariate analysis for EGF
The incidence of the more common risk factors was compared between patients who experienced EGF and those who did not (Table 1) . A statistically significant difference emerged in terms of recipient sex, redo surgery and current hospitalization at the moment of HT. Interestingly, EGF rarely occurred in female recipients (1.6%). Preoperative haemoglobin difference was partially statistically significant even though not clinically relevant (12.4 vs. 13 g/dl). Risk factors related to the donor were: high inotropic support at the time of harvest and total ischaemic time. Modifiable factors related to the procedure were: D/R weight mismatch, higher postoperative troponin peak and units of red blood cells transfused.
Bivariate analysis between propensity score groups EGF occurred in 2.9, 3.8 and 23.6%, respectively, in the three tertiles of risk according to the propensity score. Overall, glomerular filtration rate-related mortality was 56.3% (100, 75 and 48%, respectively, in the three groups). Univariate analysis between the high-risk group and the remaining population disclosed that in high-risk patients the incidence of EGF, acute kidney injury (a perioperative change in modification of diet in renal disease (MDRD) GFR >50%), MOF, hospital mortality and 1-year mortality were statistically higher (Table 2) . Interestingly, no differences emerged in terms of the rate of infections during the first postoperative year, and there was a higher 1-year conditioned to 30-day survival in the low-intermediate risk group. In Fig. 1 relative risks are reported for the mentioned outcomes.
The analysis comparing the two propensity score derived clinical profiles showed that the group at higher risk for EGF had higher prevalence of male sex, non-idiopatic cardiomiopathy, redo operations (52.8 vs. 4.7%) and hospitalized patients (42.5%; Table 3 ). In Fig. 1 , the relative risks of every risk factor evidenced in the high-risk group are shown. In these weaker patients, we had to accept implantation of organs with higher donor age, more frequent weight D/R mismatch, longer total ischaemic time, higher incidence of high donor's inotropic support and resulting in higher troponin peak. The larger use of red blood cell transfusions in these patients could be related to the higher prevalence of redo procedures.
DISCUSSION
In our experience, EGF occurred in 10.1% of the overall population (16.3% of in-hospital patients).
These data are similar to those issued by the International Registries [4] . Any statistical analysis attempting to identify risk Data are presented as the mean ± SD or counts (percentages). Column percentages are presented.
ORIGINAL ARTICLES
C. Amarelli et al. / Interactive CardioVascular and Thoracic Surgeryfactors in a small series of patients is challenging and strongly biased by the selection criteria adopted to warrant the best outcome to the individual patient. For example, the higher incidence of EGF observed in patients in higher surgical priority may be due to the declining clinical conditions that indeed prevented an optimal donor/recipient size match. Overall, EGF-related mortality was 56.3%. These data could be considered good in comparison with those forwarded by Russo et al. [10] or Ibrahim et al. [11] , but this could be due to the stricter definition of EGF in our experience compared with others.
The pathophysiology that underlies EGF is generally multifactorial. The present analysis underscores this complexity, mainly related to the interdependence of some of the identified risk factors, which variably interact with each other in determining the individual patient's risk [12, 13] . Thus, a main message is that EGF risk cannot be quantified in the single recipient unless donor and procedure factors are known and taken into account. Therefore, the modifiable components of the pathogenesis could change from case to case, in order to avoid the untoward synergism between recipient conditions and donor features that have been proved to interact in EGF development.
Interestingly, haemodynamically significant RV dysfunction rarely occurred in our series in patients with higher pulmonary vascular resistance. This indicates that in this case the D/R match was carefully made to avoid any problem [14] . This is also due to the fact that patients were carefully screened and monitored for the development of pulmonary vascular hypertension while waiting for a suitable donor organ.
The synergistic effect, in terms of higher incidence of EGF, of redo operations and higher blood products consumption observed in our series suggests that surgical haemostasis during reopening or during implantation should be as meticulous as possible even in the constraint of higher ischaemic time. Nevertheless, every effort should be spent to reduce ischaemic time due to the movement of the harvesting team [15] . The correlation between ATG Fresenius usage and EGF could be explained with the strong selection bias operated at our institution. On the basis of our previous experience [7] , ATG Fresenius was generally preferred to thymoglobuline when the patient was considered too weak. However, a less efficient protection from the ischaemia/reperfusion damage of the ATG in comparison with thymoglobuline could be also responsible for the association with EGF. This issue remains to be addressed.
All in all, the lesser number of patients dying of EGF could be due to the activity of a large volume centre for HT giving a good chance of optimal D/R matching. In some cases (i.e. rare groups, high surgical priority, immunized or obese recipients), the policy of allocation probably should be modified in order to obtain the best nationwide match.
Limitations of the study
This study comes from a single-centre experience and this accounts for the lower number of patients in some subgroups (i.e. ventricular assist device explanation) that could hide the effect of some risk factor well recognized in the Registries and in the cardiac transplant research database. Data were also strongly affected by local clinical practice that could mask the power of some undetected risk factors. Nevertheless, this could be considered as the real world experience of a well-trained group in HT.
Conclusions
Several donor and recipient features proved determinants of EGF. Since such characteristics are not readily modifiable but synergistically determine the occurrence of EGF, optimization of D/R matching is crucial to reduce the risk of EGF. Different groups of patients showed a significantly different risk of EGF; a score risk for EGF could help in calculate the individual risk of EGF before surgery and elucidate it to the patient at the time of informed consent. Changes in allocation rules in urgent recipients and in recipients with rare groups, immunized or obese, should be considered looking at the general interest of nationwide listed patients. Changes in strategies of myocardial protection for marginal donors with a long ischaemic time should be evaluated to better protect allograft function, achieve a good haemostasis and warrant good outcomes. 
